Article

When to consider corneal cross-linking treatment

Author(s):

Julianne Mobilian
Conferences|ASCRS

Audrey Talley Rostov, MD, discusses corneal cross-linking (CXL) complications, and when to consider CXL treatment 

Audrey Talley Rostov, MD, discusses corneal cross-linking (CXL) complications, and when to consider CXL treatment at the 2019 annual ASCRS meeting in San Diego.

RELATED: Intense pulsed light therapy for the treatment of chalazia

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times) ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
Related Content
Viridian Therapeutics announces positive long-term durability data for veligrotug for the treatment of active thyroid eye disease
May 20th 2025

Viridian Therapeutics announces positive long-term durability data for veligrotug for the treatment of active thyroid eye disease

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

(Image credit: AdobeStock/peshkova)
May 17th 2025

Q&A: Joaquin De Rojas, MD, on ASCRS 2025 Best Paper of Session for advancing AK with machine learning

Ehsan Sadri, MD, and Colin Green, PhD: How a noninvasive eye drop therapy could transform keratoconus care
September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops
May 10th 2025

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops

Belantamab mafodotin–induced corneal changes in patients with multiple myeloma
May 10th 2025

Belantamab mafodotin–induced corneal changes in patients with multiple myeloma

© 2025 MJH Life Sciences

All rights reserved.